Skip to playerSkip to main content
Benzinga
  • 7 weeks ago
Novo Nordisk shares plunged after its next-gen obesity drug failed to keep pace with Eli Lilly’s blockbuster weight-loss therapy.

Category

🗞
News
Comments

Recommended

Eli Lilly Pill Approval
Benzinga
2 weeks ago
Novo-Hims Wegovy Deal
Benzinga
5 weeks ago
Eli Lilly Stock Slips
Benzinga
3 months ago
Hims Shares Fall
Benzinga
2 months ago
1 in 8 Americans Have Tried Ozempic & Weight Loss Drugs: New Survey
Creator Connect
2 months ago
Artemis II Crew Returns to Earth After Historic Lunar Voyage
Cheddar News
4 days ago
White House Warned Staff Against Iran War Prediction Market Bets
Cheddar News
4 days ago
Strait of Hormuz Remains Closed Despite U.S.-Iran Ceasefire
Cheddar News
5 days ago
haulover inlet boats
BoatSnaps
5 years ago
Court Lifts Ballroom Block
Benzinga
12 hours ago
Ackman IPO Roadshow
Benzinga
13 hours ago
IBM DEI Settlement
Benzinga
13 hours ago
Mario Sequel Holds Strong
Benzinga
13 hours ago
Goldman Revenue Record
Benzinga
13 hours ago
Wegovy Pill Launches In U.S.
Benzinga
3 months ago
FDA Clears GLP-1 Pill
Benzinga
4 months ago
Behind the scenes at Novo Nordisk’s Wegovy production plant
TIME
3 months ago
Novo Nordisk Launches First GLP-1 Weight Pill
Cheddar News
3 months ago
FDA approves Wegovy GLP-1 pill, pushing weight-loss drugs into new era
Straight Arrow News
4 months ago
Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound
Bloomberg
4 months ago
Pfizer Clinches $10B Deal For Obesity Drug Maker, Beating Novo In Fierce Bidding War
Benzinga
5 months ago
Novo Nordisk Shares Jump After CEO Predicts Wegovy Recovery as Compounded Drugs Exit U.S. Market
Benzinga
11 months ago
Novo Nordisk Shares Drop 27% After Obesity Drug Trial Fails to Meet Expectations
Benzinga
1 year ago
Weight Loss Bubble? Investors Bullish on Novo Nordisk and Eli Lilly as Obesity Epidemic Drives Sales of Ozempic and Wegovy
Benzinga
3 years ago
Novo Nordisk's new obesity drug data disappoints again, shares fall
Bangkok Post Group
1 year ago